CCM
ONCE

Cadian Capital Management’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

Cadian Capital Management’s Portfolio ONCE Stock Details ONCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-30,000
Closed -$1.79M – 50
2017
Q2 		$1.79M Buy
+30,000
New +$1.68M 0.09% 40

Other funds holding ONCE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Cadian Capital Management's ONCE Position: Q3 2017 in Review

Cadian Capital Management sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q3 2017, closing a stake of 30,000 shares — an estimated $1.79M sold.

Cadian Capital Management first reported a position in ONCE in Q2 2017 and held it in 1 quarter. The position peaked at $1.79M in Q2 2017. 163 funds tracked by Wall St. Rank hold ONCE as of Q3 2017.

  • Cadian Capital Management reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
  • Cadian Capital Management sold 30,000 Spark Therapeutics, Inc. Common Stock shares in Q3 2017, an estimated $1.79M.
  • Cadian Capital Management first reported a position in Spark Therapeutics, Inc. Common Stock in Q2 2017 and held it in 1 quarter.
  • Cadian Capital Management's Spark Therapeutics, Inc. Common Stock position peaked at $1.79M in Q2 2017.
  • 163 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q3 2017.

Based on Cadian Capital Management's 13F filing for Q3 2017, filed 13 Nov 2017.